Arca Biopharma (ABIO) Reports Q2 Loss of $0.10/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Arca Biopharma (ABIO) Reports Q2 Loss of $0.10/Share

ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments

August 11, 2015 4:00 PM EDT

GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation

Phase 2B of GENETIC-AF Projected to Complete Enrollment by Year-End 2016

WESTMINSTER, Colo.--(BUSINESS WIRE)-- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2015, and provided an update on recent accomplishments.

This quarter was productive for ARCA. We strengthened our financial position through a successful equity offering that resulted in net proceeds of approximately $34 million, which we believe... More